Generic semi-automated radiofluorination strategy for single domain antibodies: [18F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer

Autor: Herlinde Dierick, Laurent Navarro, Hannelore Ceuppens, Thomas Ertveldt, Ana Rita Pombo Antunes, Marleen Keyaerts, Nick Devoogdt, Karine Breckpot, Matthias D’Huyvetter, Tony Lahoutte, Vicky Caveliers, Jessica Bridoux

Publikováno v: EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-14 (2024)

Abstract Background Radiofluorination of single domain antibodies (sdAbs) via N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB) has shown to be a promising strategy in the development of sdAb-based PET tracers. While automation of the prosthetic group

Externí odkaz: https://doaj.org/article/c33569c4b08a436991ec3e0f3cbbf9ab

Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT

Autor: Katty Zeven, Timo W.M. De Groof, Hannelore Ceuppens, Robin Maximilian Awad, Thomas Ertveldt, Wout de Mey, Fien Meeus, Geert Raes, Karine Breckpot, Nick Devoogdt

Publikováno v: Frontiers in Immunology, Vol 14 (2023)

IntroductionT cell Ig and ITIM domain receptor (TIGIT) is a next-generation immune checkpoint predominantly expressed on activated T cells and NK cells, exhibiting an unfavorable prognostic association with various malignancies. Despite the emergence

Externí odkaz: https://doaj.org/article/051a7b27d7524e158560ba763978542a

Data from Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model

Autor: Ahmet Krasniqi, Karine Breckpot, Matthias D'Huyvetter, Nick Devoogdt, Marleen Keyaerts, Robin Maximilian Awad, Yannick De Vlaeminck, Hannelore Ceuppens, Quentin Lecocq, Cleo Goyvaerts, Wout de Mey, Hanne Locy, Kirsten De Ridder, Lien De Beck, Thomas Ertveldt

Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 (177Lu) represents a new and growing type of cancer therapy. We studied immunologic changes in response to TRT with 177Lu labeled anti-human CD20 camelid single domain antibod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a371709b35ee535482c91b0dd585fceb
https://doi.org/10.1158/1535-7163.c.6543403.v1

Emerging applications of nanobodies in cancer therapy

Autor: Robin Maximilian, Awad, Fien, Meeus, Hannelore, Ceuppens, Thomas, Ertveldt, Heleen, Hanssens, Quentin, Lecocq, Lukasz, Mateusiak, Katty, Zeven, Hana, Valenta, Timo W M, De Groof, Yannick, De Vlaeminck, Ahmet, Krasniqi, Kim, De Veirman, Cleo, Goyvaerts, Matthias, D'Huyvetter, Sophie, Hernot, Nick, Devoogdt, Karine, Breckpot

Publikováno v: International review of cell and molecular biology. 369

Cancer is a heterogeneous disease, requiring treatment tailored to the unique phenotype of the patient's tumor. Monoclonal antibodies (mAbs) and variants thereof have enabled targeted therapies to selectively target cancer cells. Cancer cell-specific

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5efb9206e5f2b488b5acb059570c4402
https://pubmed.ncbi.nlm.nih.gov/35777863

Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade

Autor: Thomas Ertveldt, Cleo Goyvaerts, Quentin Lecocq, Yannick De Vlaeminck, Karine Breckpot, Marleen Keyaerts, Katty Zeven, Magali Verdonck, Alexander Van Parys, Geert Raes, Hannelore Ceuppens, Katrijn Broos, Robin Maximilian Awad, Anje Cauwels, Nick Devoogdt, Lien De Beck

Publikováno v: MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss, Pp 172-182 (2021)
Molecular Therapy. Methods & Clinical Development

Monoclonal antibodies that target the inhibitory immune checkpoint axis consisting of programmed cell death protein 1 (PD-1) and its ligand, PD-L1, have changed the immune-oncology field. We identified K2, an anti-human PD-L1 single-domain antibody f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6945fe277ec73c49215f61e579e0d0
https://biblio.vub.ac.be/vubir/formatting-and-genebased-delivery-of-a-human-pdl1-single-domain-antibody-for-immune-checkpoint-blockade(1802bee6-2390-463a-87e8-147406727b9c).html